Northern Trust Corp Acquires 123,584 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Northern Trust Corp increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 11.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,160,001 shares of the company's stock after purchasing an additional 123,584 shares during the quarter. Northern Trust Corp owned 0.93% of Vaxcyte worth $94,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of PCVX. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte during the 4th quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new stake in Vaxcyte during the fourth quarter valued at approximately $41,000. Blue Trust Inc. increased its holdings in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its position in Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent research reports. Cantor Fitzgerald started coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating for the company. The Goldman Sachs Group cut their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Bank of America cut their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Price Performance

Shares of PCVX stock traded down $0.29 during trading hours on Friday, hitting $31.16. The stock had a trading volume of 2,030,375 shares, compared to its average volume of 1,309,427. The stock's 50-day moving average price is $46.66 and its two-hundred day moving average price is $74.46. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period last year, the firm earned ($0.85) EPS. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.